Home > Boards > US Listed > Biotechs > Avita Medical Ltd. (RCEL)

Evidently mant Australian retail investors believe that a

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
melody432 Member Profile
 
Followed By 2
Posts 534
Boards Moderated 0
Alias Born 07/12/16
160x600 placeholder
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference Business Wire - 5/21/2020 4:01:00 PM
AVITA Medical to Participate at Oppenheimer's MedTech Summit Business Wire - 5/13/2020 4:01:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/12/2020 11:00:49 AM
AVITA Medical Limited Proposed Redomiciliation to the United States of America – Registration of Scheme Booklet with ASIC &... Business Wire - 5/11/2020 4:31:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/11/2020 12:22:49 PM
AVITA Medical Limited Proposed redomiciliation to the United States of America – Federal Court of Australia orders convenin... Business Wire - 5/11/2020 11:47:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/29/2020 2:14:54 PM
AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update Business Wire - 4/29/2020 1:10:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/20/2020 5:25:55 PM
AVITA Medical Announces Intention to Redomicile to the United States of America Business Wire - 4/20/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/15/2020 6:01:04 AM
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update Business Wire - 4/6/2020 8:00:00 AM
RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online Business Wire - 4/1/2020 8:35:00 PM
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL® System for Pediatric Scald Injuries Business Wire - 3/4/2020 4:01:00 PM
AVITA Medical to Attend the 2020 BTIG Healthcare Conference Business Wire - 3/3/2020 4:05:00 PM
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction Business Wire - 3/2/2020 10:21:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/19/2020 4:28:21 PM
AVITA Medical Half-Year Financial Report for Fiscal 2020 Business Wire - 2/19/2020 1:04:00 AM
AVITA Medical to Present at the Cowen 40th Annual Health Care Conference Business Wire - 2/11/2020 4:05:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/3/2020 12:28:14 PM
AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update Business Wire - 1/30/2020 7:38:00 PM
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL Sy... Business Wire - 12/29/2019 6:49:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 12/6/2019 6:02:01 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/27/2019 4:39:02 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 11/27/2019 4:26:10 PM
melody432   Wednesday, 04/29/20 01:41:15 PM
Re: None
Post # of 5724 
Evidently mant Australian retail investors believe that a small cap biotech company with a recently approved product should have declining sales and marketing expenses soon after launch. Why they believe this is beyond my meager intellect. Avita's burn rate is lower than many small cap biotechs I've followed, most of which don't even have an approved product. I do believe Covid19 has pushed back timelines, but that's true for at least 90% of business. Like the rest of the market it's going to bounce around for awhile. Shouldn't be news to anyone at this point.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist